Molecular Partners (MOLN)
NASDAQ:MOLN
Top Page
Molecular Partners
(NASDAQ:MOLN)
Select Model
Select Model
Rating:43Neutral
Price Target:
$3.50
▼(-9.09% Downside)
Action:ReiteratedDate:03/18/26
The score is weighed down primarily by collapsing revenue and persistent cash burn (weak financial performance), with additional pressure from negative technical momentum (below key moving averages with negative MACD). Valuation is also constrained by losses (negative P/E) and no dividend support.
Positive Factors
Platform validation
MP0712 first-in-human imaging and dosimetry demonstrated specific tumor targeting and limited off-target uptake, validating the Radio-DARPin delivery approach. Platform validation raises the probability of clinical success, supports regulatory dialogue and makes the tech more attractive to partners and acquirers.
Negative Factors
Revenue collapse
The drop to zero product/partner revenue by 2025 removes recurring internal cash generation, forcing reliance on milestone receipts, licensing or financing. This structural revenue loss reduces self-funding capacity for R&D and increases execution risk for multi-year clinical programs and commercialization plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform validation
MP0712 first-in-human imaging and dosimetry demonstrated specific tumor targeting and limited off-target uptake, validating the Radio-DARPin delivery approach. Platform validation raises the probability of clinical success, supports regulatory dialogue and makes the tech more attractive to partners and acquirers.
Read all positive factors
Molecular Partners (MOLN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$162.48M
Dividend YieldN/A
Average Volume (3M)2.31K
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue Growth-100.00%
EPS Growth11.02%
CountryUS
Employees158
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding40,374,640
10 Day Avg. Volume2,377
30 Day Avg. Volume2,311
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)1.60
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.99
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$11.00Price Target Upside185.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.74
Revenue Forecast (FY)$6.83M
Molecular Partners Business Overview & Revenue Model
Company Description
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is ...
How the Company Makes Money
Molecular Partners primarily generates revenue from partnering activities tied to its DARPin-based drug candidates and technology platform. Key revenue streams include: (1) upfront payments received when entering collaboration and license agreemen...
Molecular Partners Earnings Call Summary
Earnings Call Date:Mar 06, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 31, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in Molecular Partners' programs, particularly in the radio DARPin franchise and the improved efficacy of the 533-DARPIn program. The expansion of the Orano Med collaboration and strong financial position further bolster the company's outlook. However, the discontinuation of the Novartis collaboration and initial challenges with the T Cell Engager program were noted as setbacks. Overall, the highlights significantly outweigh the lowlights.Positive Updates
Successful Year of Execution
Molecular Partners successfully executed their plans in 2024, advancing programs toward clinical readouts and expanding their collaboration with Orano Med.
Negative Updates
Discontinuation of Novartis Collaboration
The collaboration with Novartis was discontinued after three years due to lack of strategic interest in the research targets.
Read all updates
Q4-2024 Updates
Positive
Negative
Successful Year of Execution
Molecular Partners successfully executed their plans in 2024, advancing programs toward clinical readouts and expanding their collaboration with Orano Med.
Read all positive updates
Company Guidance
During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several key metrics and strategic developments were highlighted. The company reported operating expenses of CHF 66 million for the year, which was within their guidance range of CHF 65 million to CHF 70 million. They ended the year with a cash balance of CHF 149 million, having raised CHF 20 million in a financing round in October, and reported a cash burn of approximately CHF 54 million for the year. This funding positions them well financially, with a runway extending into 2027. Revenue for 2024 was CHF 5 million, primarily from their collaboration with Novartis, which has now concluded. The company is advancing its radio DARPin program, with their lead candidate MP0712 set to begin clinical trials and dosimetry studies in 2025. The expansion of their collaboration with Orano Med was also a significant milestone, securing access to 10 product slots for the promising isotope Lead-212. Additionally, Molecular Partners is continuing to refine its T cell engager platform, with plans to densify dosing schedules and further investigate premedication strategies in upcoming trials.Molecular Partners Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 4.97M | 7.04M | 189.56M | 9.33M |
| Gross Profit | 0.00 | -42.53M | -40.81M | 138.81M | -46.39M |
| EBITDA | -59.49M | -51.65M | -59.52M | 119.00M | -60.66M |
| Net Income | -61.65M | -54.04M | -61.98M | 117.85M | -63.78M |
Balance Sheet | |||||
| Total Assets | 102.11M | 158.53M | 198.35M | 262.26M | 172.67M |
| Cash, Cash Equivalents and Short-Term Investments | 93.06M | 149.44M | 186.89M | 249.14M | 132.81M |
| Total Debt | 3.64M | 2.44M | 3.65M | 4.85M | 6.04M |
| Total Liabilities | 21.77M | 16.89M | 21.92M | 27.09M | 65.38M |
| Stockholders Equity | 80.33M | 141.64M | 176.43M | 235.17M | 107.29M |
Cash Flow | |||||
| Free Cash Flow | -51.97M | -59.97M | -59.81M | 117.15M | -92.26M |
| Operating Cash Flow | -51.26M | -59.25M | -59.01M | 118.57M | -90.95M |
| Investing Cash Flow | 72.55M | 40.49M | 44.64M | -101.12M | -22.24M |
| Financing Cash Flow | -1.15M | 14.43M | -1.17M | -1.57M | 50.58M |
Molecular Partners Technical Analysis
Negative
3.85
Price Trends
4.54
Negative
4.40
Negative
4.06
Negative
Market Momentum
-0.20
Positive
31.68
Neutral
23.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MOLN, the sentiment is Negative. The current price of 3.85 is below the 20-day moving average (MA) of 4.42, below the 50-day MA of 4.54, and below the 200-day MA of 4.06, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 31.68 is Neutral, neither overbought nor oversold. The STOCH value of 23.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MOLN.
Molecular Partners Risk Analysis
Molecular Partners disclosed 102 risk factors in its most recent earnings report. Molecular Partners reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Molecular Partners Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $213.69M | 4.04 | 55.68% | ― | -88.47% | -1658.33% | |
52 Neutral | $275.17M | -1.51 | -53.83% | ― | -10.57% | 1.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $459.44M | -7.52 | -65.03% | ― | -84.46% | 33.32% | |
49 Neutral | $111.52M | -2.91 | -1292.68% | ― | ― | ― | |
44 Neutral | $165.39M | -1.32 | -30.02% | ― | ― | 25.84% | |
43 Neutral | $162.48M | -2.09 | -49.86% | ― | -100.00% | 11.02% |
* Healthcare Sector Average
MOLN
Molecular Partners
3.85
0.31
8.76%
CGEN
Compugen
2.26
1.00
79.37%
ONCY
Oncolytics Biotech
0.96
0.43
82.16%
NKTX
Nkarta
2.32
0.76
48.72%
CCCC
C4 Therapeutics
2.82
1.49
112.03%
STTK
Shattuck Labs
6.42
5.12
393.85%
Molecular Partners Corporate Events
Molecular Partners Sets 2026 AGM, Nominates Clare Fisher to Board as Long-Serving Director Steps Down
Mar 30, 2026
On March 23, 2026, Molecular Partners published its invitation to the 2026 Annual General Meeting, scheduled for April 14, 2026 in Schlieren, Switzerland, and proposed industry veteran Clare Fisher for election to the Board of Directors. The compa...
Molecular Partners Posts 2025 Results, Advances Radio-DARPins and Oncology Pipeline
Mar 13, 2026
On March 12, 2026, Molecular Partners reported its 2025 audited financial results and corporate highlights, underscoring a cash position of CHF 93.1 million that is expected to fund operations into 2028 and support the expansion of its oncology pi...
Molecular Partners Publishes 2025 Report as Radio-DARPin Pipeline Enters Key Clinical Phase
Mar 12, 2026
On March 12, 2026, Molecular Partners AG filed a Form 6-K noting the publication of its 2025 Annual Report, highlighting a year of scientific and financial milestones. The company advanced its lead Radio-DARPin MP0712 into a U.S. Phase 1/2a trial ...
Molecular Partners Unveils First Human Data for DLL3-Targeting Radio-DARPin MP0712 at TWC 2026
Feb 2, 2026
On February 2, 2026, Molecular Partners announced that first-in-human imaging and dosimetry data for its DLL3-targeting Radio-DARPin candidate MP0712 were presented at the 8th Theranostics World Congress in Cape Town, covering data generated betwe...
Molecular Partners Launches New Clinical Trials and Maps 2026 Milestones Ahead of J.P. Morgan Healthcare Conference
Jan 12, 2026
On January 11, 2026, Molecular Partners reported broad clinical and pipeline progress ahead of its presentation at the 44th J.P. Morgan Healthcare Conference, underscoring its push to establish leadership in targeted radiotherapeutics and novel im...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.